Paclitaxel

Catalog No.S1150 Synonyms: NSC 125973

Molecular Weight(MW): 853.91

Paclitaxel is a microtubule polymer stabilizer with IC50 of 0.1 pM in human endothelial cells.

Cited by 22 Publications

Nature, 2017, 551(7679):247-250

PubMed: 29088702 ( click the link to review the publication )

Sci Transl Med, 2018, 10(433)

PubMed: 29563317 ( click the link to review the publication )

Science, 2017, eaal3755

PubMed: 28302793 ( click the link to review the publication )

Nat Chem Biol, 2016, 10.1038/nchembio.2082

PubMed: 27182663 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(13):3197-3203

PubMed: 29559562 ( click the link to review the publication )

Clin Cancer Res., 2017, 23(15):4364-4375

PubMed: 28246274 ( click the link to review the publication )

ACS Appl Mater Interfaces, 2015, 10.1021/am5090226

PubMed: 25811662 ( click the link to review the publication )

Biomacromolecules, 2014, 15(11):4187-94

PubMed: 25251833 ( click the link to review the publication )

Int J Radiat Oncol, 2015, 91(4):807-16

PubMed: 25752395 ( click the link to review the publication )

Biochem Pharmacol, 2015, 10.1016/j.bcp.2015.05.005

PubMed: ( click the link to review the publication )

Am J Cancer Res, 2017, 7(4):903-912

PubMed: 28469962 ( click the link to review the publication )

Mol Pharmacol, 2014, 85(3):408-19

PubMed: 24353313 ( click the link to review the publication )
Mol Pharmacol, 2014, 85(3):408-19

PubMed: 24353313 ( click the link to review the publication )

Surgery, 2014, 10.1016/j.surg.2014.10.007

PubMed: ( click the link to review the publication )

Am J Physiol Heart Circ Physiol, 2012, 71(13):4707-19

PubMed: 21555371 ( click the link to review the publication )

BMC Cancer, 2012, 12:541

PubMed: 23171055 ( click the link to review the publication )

RSC Adv, 2011, 1:884-892

PubMed: ( click the link to review the publication )

Bioorg Med Chem, 2012, 21(4):922-31

PubMed: 23306053 ( click the link to review the publication )

PLoS One, 2016, 11(5):e0155052

PubMed: 27148873 ( click the link to review the publication )

PLoS One, 2015, 10(4):e0123901

PubMed: 25875914 ( click the link to review the publication )

Biochem Biophys Res Commun, 2014, 453(3):392-7

PubMed: 25268318 ( click the link to review the publication )

J Nanopart Res, 2014, 16:2340

PubMed: ( click the link to review the publication )

6 Customer Reviews

(F) Kaplan-Meier curves are shown for all groups described: no hydrogel, a hydrogel loaded with paclitaxel, or a hydrogel loaded with doxorubicin. The number of mice per group (n) and median survival (ms) are listed. The experiment was performed at least three times.

Science, 2018, 10(433), doi: 10.1126/scitranslmed.aar1916. Paclitaxel purchased from Selleck.

Effect of tivantinib on the mitotic index was compared with the antimitotic drugs paclitaxel and vinblastine after overnight treatment of the HLE cell line with two different concentrations of each drug.

Clin Cancer Res, 2017, 23(15):4364-4375. Paclitaxel purchased from Selleck.
Characterization of nuclear damage by PARP as DNA damage repair marker. CLSM images of dual drug conjugated nanoparticle treatments to HeLa cells for 24 h at their respective IC50 drug dosages compared to nontreated control. Cells were stained with PARP-Alexafluor 488 antibody (green).

ACS Appl Mater Interfaces, 2015, 7(14): 7584-98. Paclitaxel purchased from Selleck.

Inhibitory effect of lenvatinib and paclitaxel on the proliferation of ATC cells. Cells were treated with the indicated concentrations of lenvatinib (A) and paclitaxel (B) for 48 h, followed by MTT assay to evaluate cell proliferation. IC50 values of these two drugs for each cell line were calculated using the Reed-Muench method

Am J Cancer Res, 2017, 7(4):903-912. Paclitaxel purchased from Selleck.
Western blot analysis of pPRAS40 (T246), pS6 (S240/S244), and pS6 (S235/S236) proteins in (A) HeyA8 cells and (B) SKOV3 cells treated with 0.37 μM or 10 μM paclitaxel in three-dimensional cell culture for 24 hours.

PLoS One, 2016, 11(5):e0155052. . Paclitaxel purchased from Selleck.

Microscope image (406) magnification of U937 cells after exposure to SM-TNs. a) Untreated U937 cells. b) U937 cells treated with 200 nM, and 35 nM ODS empty shells. c) U937 cells treated with microcrystalline (free) Taxol prepared by sonicating Taxol in 20%H3PO4/0.8% SDS solution. d) U937 cells treated with 200 nM SM-TN. A SM-TN is seen in the middle of the picture. e) U937 cells treated with 35 nM SMTN.The nanowires are too small to see at this magnification, but their effect on the cells is clearly visible. Scale bar = 10 mm.

RSC Adv 2011 1, 884-892. Paclitaxel purchased from Selleck.

Purity & Quality Control

Choose Selective Microtubule Associated Inhibitors

Biological Activity

Description

Paclitaxel is a microtubule polymer stabilizer with IC50 of 0.1 pM in human endothelial cells.

Targets

Microtubule (human endothelial cells) ^[1]

0.1 pM

In vitro

Paclitaxel inhibits non-endothelial type human cells at 10⁴ - to 10⁵ -fold higher concentrations, with IC50 of 1 nM-10 nM. The selectivity of Paclitaxel inhibition of cell proliferation is also species specific, as mouse ECs are not sensitive to Paclitaxel at ultra low concentrations. Inhibition of human ECs by Paclitaxel at ultra low concentrations does not affect the cellular microtubule structure, and the treated cells do not show G2/M cell cycle arrest and apoptosis, suggesting a novel but as yet unidentified mechanism of action. In an in vitro angiogenesis assay, Paclitaxel at ultra low concentrations blocks human ECs from forming sprouts and tubes in the three-dimensional fibrin matrix. ^[1] In the presence of SMF, the efficient concentration of Paclitaxel on K562 cells is decreased from 50 to 10 ng/mL. The cell cycle arrest effect of Paclitaxel with or without SMF on K562 cells is correlated with DNA damage. ^[2] Paclitaxel alone causes a time-dependent inhibition of CDK1 in four cell lines including A549 cells, H358, H1395 cells and H1666 cells. ^[3]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
TE-15	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV7JR\|UxRTBwMECwNlg4KM7:TR?=	NHfSTHZUSU6JRWK=
LC-2-ad	NVfyfYJnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1[1RmlEPTB;MD6wNFA{OTdizszN	MULTRW5ITVJ?
RL95-2	MmToS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV7jT4IzUUN3ME2wMlAxODZ4ODFOwG0>	NFz2NmxUSU6JRWK=
MZ1-PC	Mn\wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF7FOIxKSzVyPUCuNFAxPzJ7IN88US=>	NEfGTZpUSU6JRWK=
TE-8	M3zVRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVPJR\|UxRTBwMECxNVch\|ryP	Mm[4V2FPT0WU
SW954	M4Ozb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkDDTWM2OD1yLkCwNVE6KM7:TR?=	NYL6SHFmW0GQR1XS
TE-11	NILrNlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2e2SWlEPTB;MD6wNFEzOyEQvF2=	NGnoe\|hUSU6JRWK=
PSN1	NUTT[\|F3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1\pXmlEPTB;MD6wNFE{KM7:TR?=	NWTpW25pW0GQR1XS
MOLT-4	NEDGPZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVTJR\|UxRTBwMECxOFkh\|ryP	NH\LTJNUSU6JRWK=
697	NEnwfXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVzJR\|UxRTBwMECxOUDPxE1?	MXHTRW5ITVJ?
ETK-1	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4DOe2lEPTB;MD6wNFE2OiEQvF2=	NYXqdo83W0GQR1XS
TE-10	NYLHbYNtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUXwUnBOUUN3ME2wMlAxOTV2IN88US=>	NXnMdlI1W0GQR1XS
HUTU-80	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIrwcFVKSzVyPUCuNFAyPjhizszN	NUnvXVJKW0GQR1XS
NTERA-S-cl-D1	NFThbVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NETXUo1KSzVyPUCuNFAzODlizszN	NVTDPIV5W0GQR1XS
MFH-ino	NIDrXGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFXRNIVKSzVyPUCuNFAzPjhizszN	M2GwVHNCVkeHUh?=
IA-LM	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYnnRYpHUUN3ME2wMlAxOjhizszN	NH\tc45USU6JRWK=
MC116	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEHX[\|ZKSzVyPUCuNFAzQDlizszN	NWSzT3NCW0GQR1XS
RKO	NFyyVmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{PGOmlEPTB;MD6wNFI6QCEQvF2=	MVfTRW5ITVJ?
MRK-nu-1	NWLHeHBrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2PhTGlEPTB;MD6wNFI6QSEQvF2=	MnuwV2FPT0WU
VA-ES-BJ	M4qxTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoLSTWM2OD1yLkCwN{DPxE1?	NFTXXVhUSU6JRWK=
KALS-1	Ml\aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV;5eYV7UUN3ME2wMlAxOzB6IN88US=>	NX:wPVhkW0GQR1XS
BB30-HNC	NWnD[5kxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkHjTWM2OD1yLkCwN\|E1KM7:TR?=	MYTTRW5ITVJ?
ACN	NF31XWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYPNTY9rUUN3ME2wMlAxOzF4IN88US=>	Mne3V2FPT0WU
TE-9	NF3aNGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIT1WnJKSzVyPUCuNFA{OjZizszN	NYSy[4g3W0GQR1XS
SIG-M5	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2[zVWlEPTB;MD6wNFMzPyEQvF2=	MU\TRW5ITVJ?
no-10	M4m4b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NG\mbppKSzVyPUCuNFA{PjJizszN	NI\NeW5USU6JRWK=
EW-1	M2q5T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoD1TWM2OD1yLkCwN\|cyKM7:TR?=	NWnZPWxoW0GQR1XS
SK-LMS-1	M17NUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFrjWYZKSzVyPUCuNFA1ODFizszN	NWfY[ZFXW0GQR1XS
GT3TKB	Mly4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2fp[2lEPTB;MD6wNFQ{PCEQvF2=	M1\5T3NCVkeHUh?=
ES4	NGrnTHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1vZcGlEPTB;MD6wNFQ1QSEQvF2=	NYi5ZYxMW0GQR1XS
IMR-5	Mn\rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYjJR\|UxRTBwMEC0OUDPxE1?	M4npcXNCVkeHUh?=
NCI-H1648	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF3GclJKSzVyPUCuNFA1PjlizszN	NV7rNJhEW0GQR1XS
MV-4-11	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3;4b2lEPTB;MD6wNFQ4PSEQvF2=	MXHTRW5ITVJ?
SK-UT-1	NYTjbItiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHPHUopKSzVyPUCuNFA1QCEQvF2=	M3;hbHNCVkeHUh?=
NB13	NVLJWHl{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mnm2TWM2OD1yLkCwOFkyKM7:TR?=	MVLTRW5ITVJ?
DJM-1	M{DINmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHvPOoxKSzVyPUCuNFA2OyEQvF2=	MkiwV2FPT0WU
ES8	MoSyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXvJR\|UxRTBwMEC1N\|gh\|ryP	MlHTV2FPT0WU
TE-6	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3jNZWlEPTB;MD6wNFU4KM7:TR?=	NYfYcGVLW0GQR1XS
KS-1	M{DkSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHPUNlRKSzVyPUCuNFA2QDJizszN	NVXVWHNSW0GQR1XS
TE-1	NInGZ3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUXJR\|UxRTBwMEC2NFYh\|ryP	NU\vVJFmW0GQR1XS
ATN-1	NX:zXYdRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV7SV\|hmUUN3ME2wMlAxPjB7IN88US=>	NFLwVWVUSU6JRWK=
A4-Fuk	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXXwUFF5UUN3ME2wMlAxPjFzIN88US=>	NH7BVZdUSU6JRWK=
ALL-PO	NVm3WpNxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3\DV2lEPTB;MD6wNFY{KM7:TR?=	MmrUV2FPT0WU
BE-13	MkXoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NY\v[m9sUUN3ME2wMlAxPjN4IN88US=>	NHzZeYRUSU6JRWK=
KM12	M1XZbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmjvTWM2OD1yLkCwOlM4KM7:TR?=	NWq3O3ZCW0GQR1XS
NOS-1	NID1OFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn[yTWM2OD1yLkCwOlUh\|ryP	NFPrc5BUSU6JRWK=
SW962	MmjWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlH3TWM2OD1yLkCwOlYzKM7:TR?=	NIrXUWZUSU6JRWK=
OCUB-M	NXf1fWt7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmX0TWM2OD1yLkCwOlYzKM7:TR?=	M2TMOnNCVkeHUh?=
NCI-H510A	NHj2doRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWG3fGd3UUN3ME2wMlAxPjZ3IN88US=>	M1LlSXNCVkeHUh?=
EW-16	Ml\IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3TjZWlEPTB;MD6wNFY6PCEQvF2=	M3[zUXNCVkeHUh?=
KGN	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWPJR\|UxRTBwMEC3NVIh\|ryP	NVfPcWhwW0GQR1XS
LS-411N	M2nmNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkHITWM2OD1yLkCwO\|E4KM7:TR?=	MVrTRW5ITVJ?
Becker	Mm\kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFG5V\|hKSzVyPUCuNFA4OiEQvF2=	NIDkeGhUSU6JRWK=
HC-1	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYTJR\|UxRTBwMEC3NlEh\|ryP	MVTTRW5ITVJ?
CESS	M2jWTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWrJR\|UxRTBwMEC3N\|ch\|ryP	MVrTRW5ITVJ?
KURAMOCHI	NFjDUWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYHGZoZIUUN3ME2wMlAxPzR6IN88US=>	NWru[GZLW0GQR1XS
TGBC24TKB	Mn\ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3;OS2lEPTB;MD6wNFc2OiEQvF2=	MYrTRW5ITVJ?
SW982	MmPZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn;RTWM2OD1yLkCwO\|Y3KM7:TR?=	NVPoc3o3W0GQR1XS
HCE-4	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2LDZ2lEPTB;MD6wNFc3PyEQvF2=	MWrTRW5ITVJ?
LOUCY	M3S0dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnjoTWM2OD1yLkCwO\|c2KM7:TR?=	M2W3Z3NCVkeHUh?=
8-MG-BA	M1ezbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYjJR\|UxRTBwMEC3PVYh\|ryP	M3XoS3NCVkeHUh?=
HT-144	NXnSRmpoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGfqPZdKSzVyPUCuNFA5KM7:TR?=	NVjlZ2dtW0GQR1XS
LXF-289	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXHJR\|UxRTBwMEC4NVgh\|ryP	MXHTRW5ITVJ?
RS4-11	Mm\oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVzJR\|UxRTBwMEC4N\|Yh\|ryP	NH:zN21USU6JRWK=
DEL	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1fMTWlEPTB;MD6wNFg1PSEQvF2=	NGTv[G1USU6JRWK=
OCI-AML2	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEjJRZhKSzVyPUCuNFA5PTJizszN	MVrTRW5ITVJ?
CCRF-CEM	M33MbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFrhR3pKSzVyPUCuNFA5PzFizszN	MWPTRW5ITVJ?
A388	NHjiXFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX7JR\|UxRTBwMEC4O\|Qh\|ryP	MmnUV2FPT0WU
KNS-42	M{f2eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX3JR\|UxRTBwMEC4PVEh\|ryP	NWTCTmY5W0GQR1XS
OVCAR-4	NGTGb4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3Pyc2lEPTB;MD6wNFkxPCEQvF2=	MWrTRW5ITVJ?
NCI-H1355	MkXIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnrMTWM2OD1yLkCwPVE1KM7:TR?=	MYXTRW5ITVJ?
BL-70	NWTLc\|lMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{PVVGlEPTB;MD6wNFk{KM7:TR?=	M1XaV3NCVkeHUh?=
BL-41	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3;mVGlEPTB;MD6wNFk{PCEQvF2=	M1rHVnNCVkeHUh?=
A101D	NFXPTmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M17qZmlEPTB;MD6wNFk3KM7:TR?=	NGfQNXBUSU6JRWK=
HL-60	NV:4TYluT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{DqcmlEPTB;MD6wNFk3PiEQvF2=	NVLVU3NHW0GQR1XS
COR-L279	NGTCWHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1rmR2lEPTB;MD6wNFk6QSEQvF2=	MUXTRW5ITVJ?
NCI-SNU-16	M{\VXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV7JR\|UxRTBwMEGwNFgh\|ryP	MoD4V2FPT0WU
Calu-6	NWrMVG5NT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXPJR\|UxRTBwMEGwNVIh\|ryP	MUPTRW5ITVJ?
SR	M4nSTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHPE[\|BKSzVyPUCuNFExOjZizszN	NV;BS2VqW0GQR1XS
QIMR-WIL	MoHXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXjhZYVOUUN3ME2wMlAyODN\|IN88US=>	M{e4S3NCVkeHUh?=
LB647-SCLC	NWTu[phPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHPXbXFKSzVyPUCuNFExPTFizszN	NHLYXJZUSU6JRWK=
RPMI-8226	M{[zTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWrJR\|UxRTBwMEGxNFIh\|ryP	MUTTRW5ITVJ?
SK-PN-DW	NUO5d\|lQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV3vcHlsUUN3ME2wMlAyOTF{IN88US=>	MYjTRW5ITVJ?
SF268	MlizS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUfJR\|UxRTBwMEGxOVEh\|ryP	NEnJUodUSU6JRWK=
HD-MY-Z	M2PwfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV[0ZmNVUUN3ME2wMlAyOTZ\|IN88US=>	NFXQRlZUSU6JRWK=
DOHH-2	MoHGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVf1fmtQUUN3ME2wMlAyOjB\|IN88US=>	MWrTRW5ITVJ?
SCC-3	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYD4WGw{UUN3ME2wMlAyOjB2IN88US=>	NGi4PGtUSU6JRWK=
ST486	M1HB[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWHTeHBLUUN3ME2wMlAyOjB2IN88US=>	MWLTRW5ITVJ?
NALM-6	MnTOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXHJR\|UxRTBwMEGyNVQh\|ryP	MlzFV2FPT0WU
NCI-H1436	NVLycJk6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmDSTWM2OD1yLkCxNlMyKM7:TR?=	MoPPV2FPT0WU
KE-37	NHHXUJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVzJR\|UxRTBwMEGyN\|Qh\|ryP	MVnTRW5ITVJ?
RPMI-8402	NFvFe\|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoHKTWM2OD1yLkCxNlU3KM7:TR?=	MVXTRW5ITVJ?
RXF393	MmnaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV\G[ZF{UUN3ME2wMlAyOjV5IN88US=>	NWXiNJlSW0GQR1XS
KARPAS-45	MkPjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFTrPGdKSzVyPUCuNFEzPyEQvF2=	NWrRRZZuW0GQR1XS
HOP-62	NVrWenhlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M33NemlEPTB;MD6wNVI4PiEQvF2=	M{K0bHNCVkeHUh?=
ES1	MkjtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVXOeHRGUUN3ME2wMlAyOjh6IN88US=>	M3zMWnNCVkeHUh?=
L-363	NXGxNWFvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWfJR\|UxRTBwMEGzOVEh\|ryP	NUPib2NSW0GQR1XS
GI-1	NGDoVmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWnLSmsxUUN3ME2wMlAyOzd\|IN88US=>	M2Hyb3NCVkeHUh?=
CTV-1	NInnUYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXnOcmxGUUN3ME2wMlAyPDd6IN88US=>	MVzTRW5ITVJ?
TE-5	NUX0OGFJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWfJR\|UxRTBwMEG0PVYh\|ryP	M{iweHNCVkeHUh?=
SNU-C2B	MlLSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWDJR\|UxRTBwMEG0PVYh\|ryP	Mn;2V2FPT0WU
K-562	MkLTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2DmdGlEPTB;MD6wNVUyPiEQvF2=	NEfDNGZUSU6JRWK=
SNB75	NWDuUnRxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVnUdGxNUUN3ME2wMlAyPTRizszN	MUTTRW5ITVJ?
MOLT-13	M3nyRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXfJR\|UxRTBwMEG2N\|ch\|ryP	NGHvSVdUSU6JRWK=
LS-123	MlrDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYHJR\|UxRTBwMEG2OlQh\|ryP	MWrTRW5ITVJ?
NCI-SNU-5	NGnRZmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnKxTWM2OD1yLkCxO\|AyKM7:TR?=	MoG4V2FPT0WU
Daudi	NFnRenFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1TPfmlEPTB;MD6wNVcxQCEQvF2=	MnHYV2FPT0WU
A253	NGXTR5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHq3Z5VKSzVyPUCuNFE4OzhizszN	M{fnVnNCVkeHUh?=
TGBC1TKB	M1TRemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEnZVWVKSzVyPUCuNFE4PTJizszN	NXrUPYJjW0GQR1XS
SJSA-1	NGn5XINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWm0N3pVUUN3ME2wMlAyPzZ5IN88US=>	M3n3UnNCVkeHUh?=
NCCIT	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{DQZ2lEPTB;MD6wNVc3QSEQvF2=	M{mxTXNCVkeHUh?=
NCI-H69	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX;HUpZvUUN3ME2wMlAyPzd6IN88US=>	NHfNTplUSU6JRWK=
SH-4	NETkRldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3q5[WlEPTB;MD6wNVg6PSEQvF2=	MX\TRW5ITVJ?
HCC1187	MlK2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFLOSmJKSzVyPUCuNFE6OjRizszN	MoXFV2FPT0WU
HCC1599	NV;wWndvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGf6O3NKSzVyPUCuNFIxOiEQvF2=	MlXTV2FPT0WU
ONS-76	NHrxcpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUS1W5Z4UUN3ME2wMlAzODN4IN88US=>	NG\q[\|JUSU6JRWK=
KU812	NXX3NmxtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYrJR\|UxRTBwMEKwN\|kh\|ryP	MkDtV2FPT0WU
ML-2	NVLTWHBLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUjJR\|UxRTBwMEKwOFch\|ryP	MWXTRW5ITVJ?
HCE-T	Mk\RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3fiTmlEPTB;MD6wNlA6OiEQvF2=	MoT4V2FPT0WU
NCI-H446	MnnnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmL0TWM2OD1yLkCyNVEzKM7:TR?=	NXjZ[ppJW0GQR1XS
RPMI-6666	M37EW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MY\JR\|UxRTBwMEKxOFkh\|ryP	MlTMV2FPT0WU
MOLT-16	MlrES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4D3T2lEPTB;MD6wNlE2OyEQvF2=	NHfvOplUSU6JRWK=
JiyoyeP-2003	NYHZPItYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGPlWItKSzVyPUCuNFIyPzZizszN	MkDGV2FPT0WU
MHH-PREB-1	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1Xoe2lEPTB;MD6wNlE6OSEQvF2=	M4G1PHNCVkeHUh?=
MC-CAR	NVG2W2k2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnLlTWM2OD1yLkCyN\|I3KM7:TR?=	MlG0V2FPT0WU
BC-3	NVntcZgyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2nWO2lEPTB;MD6wNlM1PCEQvF2=	NUDVfmcyW0GQR1XS
KINGS-1	M2DnWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYTHNIhmUUN3ME2wMlAzOzV3IN88US=>	M3XsVHNCVkeHUh?=
PF-382	NHrw[oNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUDyNGJ2UUN3ME2wMlAzOzd6IN88US=>	MmnKV2FPT0WU
J-RT3-T3-5	NVvweGhVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGHUNWxKSzVyPUCuNFI{QDNizszN	MWjTRW5ITVJ?
SF539	M4\uW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHiwWmFKSzVyPUCuNFI1ODFizszN	NEO3RohUSU6JRWK=
LB831-BLC	NVv6S4VkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV;6fVhmUUN3ME2wMlAzPDh3IN88US=>	MVjTRW5ITVJ?
DMS-114	M1jUNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX3JR\|UxRTBwMEK1NFIh\|ryP	MYTTRW5ITVJ?
LB1047-RCC	NWnlXlV6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1rYe2lEPTB;MD6wNlUyKM7:TR?=	NIPSTY5USU6JRWK=
LB771-HNC	NXnWfJlWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEHKTZJKSzVyPUCuNFI2OzRizszN	MnzCV2FPT0WU
BB65-RCC	M4rl[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUnSU5hOUUN3ME2wMlAzPTN2IN88US=>	M3TvWXNCVkeHUh?=
BV-173	MlHQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1G1O2lEPTB;MD6wNlU2PCEQvF2=	NEXVOIxUSU6JRWK=
ARH-77	M3TFPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkTjTWM2OD1yLkCyOlAyKM7:TR?=	MVfTRW5ITVJ?
IST-MEL1	NH3MdWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mne5TWM2OD1yLkCyOlI{KM7:TR?=	MVfTRW5ITVJ?
NB1	MoL2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mnr3TWM2OD1yLkCyOlg4KM7:TR?=	M{HW[nNCVkeHUh?=
EoL-1-cell	NVO2OW5tT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHHHfo9KSzVyPUCuNFI3QDhizszN	NWXzb\|dXW0GQR1XS
KY821	MlTiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWnYXFA4UUN3ME2wMlAzPjl5IN88US=>	M{TNOXNCVkeHUh?=
CMK	NVjtfXVVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlHITWM2OD1yLkCyO\|M1KM7:TR?=	NUfEVIJ6W0GQR1XS
NCI-H2126	NWjQRpRkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEHFdXVKSzVyPUCuNFI4PjhizszN	M4nCVHNCVkeHUh?=
NCI-H526	MnPmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1zBWWlEPTB;MD6wNlg6OSEQvF2=	MWfTRW5ITVJ?
COLO-684	MnjDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEiyNW5KSzVyPUCuNFI6ODhizszN	M4nTeXNCVkeHUh?=
NCI-H747	NV6wNYs5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NY\XNm54UUN3ME2wMlAzQTN\|IN88US=>	NEXvWnpUSU6JRWK=
JAR	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXnNXnlHUUN3ME2wMlAzQTR4IN88US=>	Ml;XV2FPT0WU
MEG-01	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXLJR\|UxRTBwMEK5O\|gh\|ryP	MkH4V2FPT0WU
MONO-MAC-6	NVHONlFlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NE\mWoRKSzVyPUCuNFMxOjNizszN	MXjTRW5ITVJ?
IST-SL1	NXzFW\|VUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFLw[YdKSzVyPUCuNFMxPDJizszN	MmS5V2FPT0WU
CPC-N	Ml:3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoiwTWM2OD1yLkCzNFc6KM7:TR?=	MVzTRW5ITVJ?
NCI-H1963	NVfON2YyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml;0TWM2OD1yLkCzNVMyKM7:TR?=	NHPkPFVUSU6JRWK=
K052	MmK0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXHjTXpYUUN3ME2wMlA{OjR5IN88US=>	MnXQV2FPT0WU
KM-H2	NXv6cWZ[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYXJR\|UxRTBwMEOzNFch\|ryP	MYLTRW5ITVJ?
TE-12	M1HBRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFLH[otKSzVyPUCuNFM{ODlizszN	M1\KWnNCVkeHUh?=
TK10	MmK5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWnCOmdvUUN3ME2wMlA{OzV4IN88US=>	MonGV2FPT0WU
NMC-G1	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoPMTWM2OD1yLkCzOFUzKM7:TR?=	NF3ZOHlUSU6JRWK=
no-11	MlPaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVjJR\|UxRTBwMEO0O\|gh\|ryP	MWXTRW5ITVJ?
NCI-H524	M3yxTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmXVTWM2OD1yLkCzOVI6KM7:TR?=	M2q3cHNCVkeHUh?=
MHH-CALL-2	M1ztNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHXl[mtKSzVyPUCuNFM2PjJizszN	MX\TRW5ITVJ?
GB-1	MkK3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEX4UWFKSzVyPUCuNFM3KM7:TR?=	MXHTRW5ITVJ?
OPM-2	NIjDbpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVnacpZ1UUN3ME2wMlA{Pjd\|IN88US=>	NFfo[IxUSU6JRWK=
RH-1	M4f2eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHTobVhKSzVyPUCuNFM5OTlizszN	M{HOUXNCVkeHUh?=
NCI-H64	M3XISmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4TWN2lEPTB;MD6wN\|g2PyEQvF2=	M3;GT3NCVkeHUh?=
EVSA-T	NVTUPWR6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml7BTWM2OD1yLkCzPVI{KM7:TR?=	NInpfmdUSU6JRWK=
KARPAS-299	M3zxZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml;ETWM2OD1yLkCzPVgh\|ryP	NGXMO\|BUSU6JRWK=
MZ7-mel	M{m5eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYHJR\|UxRTBwMESwOEDPxE1?	NFjyVFFUSU6JRWK=
LB373-MEL-D	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXnMZVZlUUN3ME2wMlA1OTB3IN88US=>	MmHsV2FPT0WU
HEL	M3HFRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWXofmpmUUN3ME2wMlA1OTRizszN	MVzTRW5ITVJ?
SW872	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mmf4TWM2OD1yLkC0NlEh\|ryP	M1P3fnNCVkeHUh?=
DU-4475	NEmxN21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFPve\|lKSzVyPUCuNFQzPDRizszN	MoHqV2FPT0WU
IST-SL2	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYrUOHVbUUN3ME2wMlA1Ojd3IN88US=>	NH3qN5RUSU6JRWK=
NCI-H82	Ml;WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mnv4TWM2OD1yLkC0N\|A4KM7:TR?=	NHrKOXFUSU6JRWK=
LC4-1	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVPGcWZXUUN3ME2wMlA1OzVzIN88US=>	NEC1Z5lUSU6JRWK=
HDLM-2	M1vxRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIDDNmVKSzVyPUCuNFQ{QTJizszN	MkL5V2FPT0WU
MMAC-SF	MljLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmrzTWM2OD1yLkC0OVM1KM7:TR?=	NF2yNnBUSU6JRWK=
L-540	NWPRV4RHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXnJR\|UxRTBwMES2N\|kh\|ryP	MV\TRW5ITVJ?
MZ2-MEL	NVXJSop2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUHXPXBQUUN3ME2wMlA1PzR{IN88US=>	MnXxV2FPT0WU
LU-134-A	M4j2PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYXnZ5RTUUN3ME2wMlA1Pzd\|IN88US=>	NXG1dHBCW0GQR1XS
UACC-257	M4HWZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoTTTWM2OD1yLkC0PFQ6KM7:TR?=	M3\NdXNCVkeHUh?=
NCI-H1581	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGrmXG5KSzVyPUCuNFQ6PTNizszN	MXXTRW5ITVJ?
NB17	NFzTdVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVvOdoJWUUN3ME2wMlA1QTd7IN88US=>	NWjsR4l3W0GQR1XS
SBC-1	M363TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoPWTWM2OD1yLkC1NFQzKM7:TR?=	NXXJc\|hHW0GQR1XS
TALL-1	MmfVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYnJR\|UxRTBwMEWwOFUh\|ryP	MkT4V2FPT0WU
NCI-H1304	NHzpSm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3S1UWlEPTB;MD6wOVIxQCEQvF2=	MY\TRW5ITVJ?
NEC8	MnnVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX;JR\|UxRTBwMEWyPFYh\|ryP	MVnTRW5ITVJ?
CAL-148	NIrRPHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmjaTWM2OD1yLkC1OFM6KM7:TR?=	MVvTRW5ITVJ?
CGTH-W-1	NXi5[4IxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUnJR\|UxRTBwMEW0OFkh\|ryP	NY\0fHNNW0GQR1XS
NCI-H889	NXe4ZoFQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3PzXWlEPTB;MD6wOVU6OiEQvF2=	NHnlfGNUSU6JRWK=
GR-ST	M4flOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGrHPG1KSzVyPUCuNFU3OjFizszN	NWjkNVNZW0GQR1XS
KARPAS-422	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXG1b2tKUUN3ME2wMlA2PjVizszN	NXz0c2I{W0GQR1XS
RPMI-8866	MkTSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV3KZZZWUUN3ME2wMlA2PzF{IN88US=>	MnfhV2FPT0WU
SCLC-21H	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVHJR\|UxRTBwMEW4PFQh\|ryP	NIPaNZFUSU6JRWK=
COR-L88	M3KwfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXK0PGF[UUN3ME2wMlA2QTJ5IN88US=>	MW\TRW5ITVJ?
LU-139	NHXFS25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYjJR\|UxRTBwMEW5PFYh\|ryP	MWLTRW5ITVJ?
SF126	M4jGRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFXPbIVKSzVyPUCuNFYyOzNizszN	MXTTRW5ITVJ?
NCI-H1882	M1flWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1TsZ2lEPTB;MD6wOlQzPCEQvF2=	NX7sdZZ5W0GQR1XS
EW-24	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXXicppCUUN3ME2wMlA3PDh\|IN88US=>	M{nnXHNCVkeHUh?=
CP67-MEL	NIPiVnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXvJR\|UxRTBwME[4NUDPxE1?	NYLOfmllW0GQR1XS
DG-75	NEm5[lRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MonlTWM2OD1yLkC2PFk6KM7:TR?=	NGjLZW5USU6JRWK=
LOXIMVI	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn[yTWM2OD1yLkC3NFI5KM7:TR?=	NF\XcmxUSU6JRWK=
HH	NV3IUFJFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MneyTWM2OD1yLkC3NVU4KM7:TR?=	M1fmOHNCVkeHUh?=
K5	NHfPbVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFTncnFKSzVyPUCuNFczOjZizszN	M{DCbXNCVkeHUh?=
EC-GI-10	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYLEb2I5UUN3ME2wMlA4OjV5IN88US=>	NFnRVldUSU6JRWK=
SK-N-DZ	MlP4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3PpVmlEPTB;MD6wO\|MxPyEQvF2=	M{DYTnNCVkeHUh?=
A3-KAW	NIXrcoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MliyTWM2OD1yLkC3N\|UyKM7:TR?=	M37XeXNCVkeHUh?=
MLMA	NHH4dJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2frSmlEPTB;MD6wO\|Q3PSEQvF2=	NXvQTI9nW0GQR1XS
LB996-RCC	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEDxbpFKSzVyPUCuNFc4ODdizszN	MUPTRW5ITVJ?
OS-RC-2	MkjCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVnJR\|UxRTBwMEe3OFgh\|ryP	NEG3WnBUSU6JRWK=
CTB-1	M{Hjbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUTJTVlCUUN3ME2wMlA4QDFizszN	M3PZTHNCVkeHUh?=
IST-MES1	NEnLc2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3\xbGlEPTB;MD6wO\|kyOiEQvF2=	NGfzNI1USU6JRWK=
LS-1034	MljGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYi2R3VtUUN3ME2wMlA5ODN3IN88US=>	M17iWXNCVkeHUh?=
HT	MoOzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXzJVW1xUUN3ME2wMlA5ODh4IN88US=>	MofhV2FPT0WU
NCI-H2141	NFfDN\|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3njcmlEPTB;MD6wPFEh\|ryP	MV;TRW5ITVJ?
LB2518-MEL	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2HTdGlEPTB;MD6wPFE1OSEQvF2=	M4LPdXNCVkeHUh?=
GI-ME-N	NFr2Z49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWLG[JZvUUN3ME2wMlA5PDV{IN88US=>	M3vHfXNCVkeHUh?=
TGW	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkS1TWM2OD1yLkC4OlA4KM7:TR?=	M{nTbnNCVkeHUh?=
SK-NEP-1	MmrKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX7JR\|UxRTBwMEi2OFEh\|ryP	Ml\SV2FPT0WU
NOMO-1	NFnOcIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFPRUFlKSzVyPUCuNFkzPzVizszN	M1;1enNCVkeHUh?=
ES6	NV7OXlBuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml3jTWM2OD1yLkC5OVg6KM7:TR?=	NWPNVGRtW0GQR1XS
NCI-H209	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVnPRZVCUUN3ME2wMlA6Pzh4IN88US=>	Mm[2V2FPT0WU
GAK	NYnYSoxYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1LTPWlEPTB;MD6xNFE3KM7:TR?=	NHXafHlUSU6JRWK=
BC-1	M4HKO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2LsRWlEPTB;MD6xNFM3OSEQvF2=	NX\kWngyW0GQR1XS
KLE	NVLVZol[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHjqc\|RKSzVyPUCuNVA1PDNizszN	M4LtV3NCVkeHUh?=
EW-3	NECwU5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYnJbJpxUUN3ME2wMlExQThizszN	NV;EZVBCW0GQR1XS
NKM-1	NFLa[WlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYjJR\|UxRTBwMUGxJO69VQ>?	NYGyOFV1W0GQR1XS
D-336MG	Mnf2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MW\JR\|UxRTBwMUGyOFQh\|ryP	MYrTRW5ITVJ?
NB69	M3vpRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkfBTWM2OD1yLkGxN\|AyKM7:TR?=	NFrMdJBUSU6JRWK=
D-263MG	NID6S\|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MljaTWM2OD1yLkGxO\|EzKM7:TR?=	M4W2ZXNCVkeHUh?=
KP-N-YS	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUfJR\|UxRTBwMUKyPVEh\|ryP	MkfaV2FPT0WU
NCI-H1155	MnrZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M17rTWlEPTB;MD6xNlU2QCEQvF2=	MUTTRW5ITVJ?
BOKU	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVzJXXVsUUN3ME2wMlEzPTd7IN88US=>	NEfGVnNUSU6JRWK=
LAMA-84	NYTQUFVWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mkf3TWM2OD1yLkGyPVkh\|ryP	MUPTRW5ITVJ?
Raji	M3vpO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHXQ[5RKSzVyPUCuNVMyOTdizszN	M3LRNnNCVkeHUh?=
LU-65	NWLHN29TT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoXMTWM2OD1yLkGzN\|A4KM7:TR?=	Mn76V2FPT0WU
NCI-H187	MoXVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXHJR\|UxRTBwMUO5NlQh\|ryP	NXfNcGcxW0GQR1XS
GCIY	M{PNS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NY\5R2lZUUN3ME2wMlE1QTBzIN88US=>	NVHifldKW0GQR1XS
NCI-H2107	NVXsfpRET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXXJR\|UxRTBwMUWwPEDPxE1?	NUWwXIR3W0GQR1XS
NCI-H1522	NVzZfFFwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{PPfWlEPTB;MD6xOVI3PiEQvF2=	M32xNXNCVkeHUh?=
NB6	MmTxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXGwfGRiUUN3ME2wMlE2PjJ\|IN88US=>	M2jsUnNCVkeHUh?=
EM-2	M4TlbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NULtcYFVUUN3ME2wMlE2PzB4IN88US=>	MUPTRW5ITVJ?
HCC2218	M4X5TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXPJR\|UxRTBwMUW5PEDPxE1?	M2H4cnNCVkeHUh?=
NCI-H748	MlTrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGfEV4JKSzVyPUCuNVY{PzZizszN	MWDTRW5ITVJ?
MS-1	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M33ufmlEPTB;MD6xOlU{PyEQvF2=	MVzTRW5ITVJ?
NB5	NUPOR\|NWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoH4TWM2OD1yLkG2OVk4KM7:TR?=	NIiwUYdUSU6JRWK=
OMC-1	Mk[1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{nObGlEPTB;MD6xOlY5QCEQvF2=	NEn5TnJUSU6JRWK=
NCI-H345	NGjGOWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEnobHhKSzVyPUCuNVY6OjhizszN	NYe4doJvW0GQR1XS
L-428	NXOydFlRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MY\JR\|UxRTBwMU[5OFUh\|ryP	M1znXnNCVkeHUh?=
SCH	M1vLeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NETLfo5KSzVyPUCuNVg3QDVizszN	MlTaV2FPT0WU
NCI-H1417	NH\t[3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGO5WldKSzVyPUCuNVkzOjdizszN	MmKyV2FPT0WU
COLO-320-HSR	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NET3NW5KSzVyPUCuNVk2OzJizszN	MljaV2FPT0WU
BT-474	Ml;iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVjQOYZHUUN3ME2wMlIxQDl{IN88US=>	Mn;sV2FPT0WU
GDM-1	NHv4[FVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4[2dGlEPTB;MD6yNVk4OSEQvF2=	NUf2V4JyW0GQR1XS
NCI-H2196	MnXjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWPMXplUUUN3ME2wMlIzOjN3IN88US=>	NFXFNIVUSU6JRWK=
KP-N-RT-BM-1	NFL4UI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX;JR\|UxRTBwMkKzOFkh\|ryP	MoTVV2FPT0WU
KNS-81-FD	M33ROGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWPPZ5d{UUN3ME2wMlIzQTV6IN88US=>	M1T0RXNCVkeHUh?=
COLO-668	Ml;yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NI[xWJJKSzVyPUCuNlM3PzVizszN	MUjTRW5ITVJ?
C2BBe1	NHfiS45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{LaZWlEPTB;MD6yOlc1PyEQvF2=	M2D2OHNCVkeHUh?=
Ramos-2G6-4C10	NU[0NHBLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXXzXotlUUN3ME2wMlI3QTV2IN88US=>	M4XyVXNCVkeHUh?=
CAS-1	MmC0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlfVTWM2OD1yLkK3NFk3KM7:TR?=	NHvZRYxUSU6JRWK=
GOTO	NHWzOotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4SwVmlEPTB;MD6yO\|g6PCEQvF2=	NWTYcVNYW0GQR1XS
LP-1	M2fLS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmnpTWM2OD1yLkK4NFU4KM7:TR?=	MX3TRW5ITVJ?
NCI-SNU-1	Moi0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYrJR\|UxRTBwMkm0NlIh\|ryP	M3Pre3NCVkeHUh?=
EB-3	MnLxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWPJR\|UxRTBwMkm5O\|kh\|ryP	NVrGRm9qW0GQR1XS
MHH-NB-11	Mnu4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MljhTWM2OD1yLkOwOFAzKM7:TR?=	NWGzVVg5W0GQR1XS
SK-N-FI	NFz5[phIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2i4[mlEPTB;MD6zNVY6OiEQvF2=	MVHTRW5ITVJ?
HCC2157	NIPxNmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHLUVJRKSzVyPUCuN\|M6OTNizszN	NVewVGg6W0GQR1XS
SIMA	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYTJR\|UxRTBwM{S1PFEh\|ryP	MX7TRW5ITVJ?
MDA-MB-134-VI	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlHkTWM2OD1yLkO2PVI5KM7:TR?=	MXzTRW5ITVJ?
NCI-H1694	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NG\PWmdKSzVyPUCuN\|ch\|ryP	MVfTRW5ITVJ?
EHEB	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NITWNJhKSzVyPUCuN\|kxQDVizszN	NY[2O5RIW0GQR1XS
U-266	M1fLZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmLsTWM2OD1yLkO5PFQ3KM7:TR?=	NGPScmZUSU6JRWK=
LC-1F	NVjidmRMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXz2eVJZUUN3ME2wMlQ{PzZ3IN88US=>	Mn[4V2FPT0WU
SHP-77	MmDmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYPJR\|UxRTBwNEe4OVUh\|ryP	M1SwV3NCVkeHUh?=
LS-513	M2nOOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUHlRZlbUUN3ME2wMlQ6OzB5IN88US=>	NWm3eIp6W0GQR1XS

... Click to View More Cell Line Experimental Data

In vivo

The inhibition rations of Paclitaxel alone on BC-V and BC-ER tumors are 49.78% and 51.23%, respectively. Treatment of six cycles of 20 mg/kg Paclitaxel significantly reduces the percentages of Ki-67-positive cells to 20.4% in BC-V tumors and 25.1% in BC-ER tumors, respectively. ^[4]

Protocol

Cell Research: ^[1]	+ Expand Cell lines: Cells including human neonatal dermal microvascular ECs (HMVECs), human umbilical vein ECs (HUVECs), human umbilical artery ECs (HUAVECs), normal human astrocytes (NHAs), normal human dermal fibroblasts (NHDFs), normal human epidermal keratinocytes (NHEKs Concentrations: 0.1-100 pM Incubation Time: 72 hours Method: Cells including human neonatal dermal microvascular ECs (HMVECs), human umbilical vein ECs (HUVECs), human umbilical artery ECs (HUAVECs), normal human astrocytes (NHAs), normal human dermal fibroblasts (NHDFs), normal human epidermal keratinocytes (NHEKs), human mammary epithelial cells (HMEpCs), human prostate epithelial cells (PrEpCs) and human umbilical artery smooth muscle cells (UASMCs) are cultured. Cell proliferations are performed in 96-well plates using cells between passages 6 and 12. Cells are seeded at 3000–5000 cells/well and allowed to attach for 4 hours. Paclitaxel, diluted in culture medium, is added in quadruplicate wells and the cells ae incubated for 3 days before MTS reagents are added to quantitate the live cells in each well. (Only for Reference)
Animal Research: ^[5]	+ Expand Animal Models: Female, 20-22 g homozygous nude athymic mice with BC-V and BC-ER tumors Formulation: Dissolved in absolute ethanol with an equal volume of cremophor and diluted 1:4 with sterile physiological saline before use. Dosages: 20 mg/kg Administration: Administered via i.v. (Only for Reference)

Cell Research:

^[1]

+ Expand

Cell lines: Cells including human neonatal dermal microvascular ECs (HMVECs), human umbilical vein ECs (HUVECs), human umbilical artery ECs (HUAVECs), normal human astrocytes (NHAs), normal human dermal fibroblasts (NHDFs), normal human epidermal keratinocytes (NHEKs
Concentrations: 0.1-100 pM
Incubation Time: 72 hours
Method:
Cells including human neonatal dermal microvascular ECs (HMVECs), human umbilical vein ECs (HUVECs), human umbilical artery ECs (HUAVECs), normal human astrocytes (NHAs), normal human dermal fibroblasts (NHDFs), normal human epidermal keratinocytes (NHEKs), human mammary epithelial cells (HMEpCs), human prostate epithelial cells (PrEpCs) and human umbilical artery smooth muscle cells (UASMCs) are cultured. Cell proliferations are performed in 96-well plates using cells between passages 6 and 12. Cells are seeded at 3000–5000 cells/well and allowed to attach for 4 hours. Paclitaxel, diluted in culture medium, is added in quadruplicate wells and the cells ae incubated for 3 days before MTS reagents are added to quantitate the live cells in each well.

(Only for Reference)

Animal Research:

^[5]

+ Expand

Animal Models: Female, 20-22 g homozygous nude athymic mice with BC-V and BC-ER tumors
Formulation: Dissolved in absolute ethanol with an equal volume of cremophor and diluted 1:4 with sterile physiological saline before use.
Dosages: 20 mg/kg
Administration: Administered via i.v.
(Only for Reference)

References

[4] Chang J, et al. Breast Cancer Res Treat. 2012.

+ Expand

Solubility (25°C)

In vitro	DMSO	171 mg/mL (200.25 mM)
	Ethanol	18 mg/mL (21.07 mM)
	Water	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 5% DMSO+5% Tween 80+ddH2O For best results, use promptly after mixing.	2.5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Paclitaxel SDF

Molecular Weight	853.91
Formula	C₄₇H₅₁NO₁₄
CAS No.	33069-62-4
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	NSC 125973

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-03-27)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03400306	Not yet recruiting	Cancer - Ovarian	AbbVie	May 10 2020	Phase 1
NCT03400306	Not yet recruiting	Cancer - Ovarian	AbbVie	May 10 2020	Phase 1
NCT03417921	Not yet recruiting	Pancreatic Cancer	Ability Pharmaceuticals SL\|The Cleveland Clinic	December 1 2019	Phase 1\|Phase 2
NCT03417921	Not yet recruiting	Pancreatic Cancer	Ability Pharmaceuticals SL\|The Cleveland Clinic	December 1 2019	Phase 1\|Phase 2
NCT03818997	Not yet recruiting	Esophageal Cancer\|Biliary Tract Cancer\|GastroEsophageal Cancer\|Hepatobiliary Neoplasm	European Organisation for Research and Treatment of Cancer - EORTC\|Hoffmann-La Roche\|Leap Therapeutics Inc.	August 2019	Phase 2
NCT03818997	Not yet recruiting	Esophageal Cancer\|Biliary Tract Cancer\|GastroEsophageal Cancer\|Hepatobiliary Neoplasm	European Organisation for Research and Treatment of Cancer - EORTC\|Hoffmann-La Roche\|Leap Therapeutics Inc.	August 2019	Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
I am interested in the product S1150 for in vivo studies, could you please give some suggestions for the formulation?
Answer:
S1150 in 1% DMSO+30% polyethylene glycol+1% Tween 80 at 30mg/ml is a suspension. If the you want to inject it, there is another vehicle, 5% DMSO+5% Tween 80+ddH2O. S1150 can dissolve in it at 2.5mg/ml as a clear solution. It is a common formulation we used, but is not cited from reference.
Question 2:
the compound was dissolved into 1ml DMSO and diluted with 1x PBS or water (500ul + 9.5 ml PBS or water). I found the white precipitation goes out. How to figure it out?
Answer:
Paclitaxel has very low solubility in water based solution and that's why it precipitated out once you dilute the stock with water. The vehicle we suggest is: 1% DMSO+30% polyethylene glycol+1% Tween 80.

Microtubule Associated Signaling Pathway Map

Related Microtubule Associated Products0

TAI-1 ^New

TAI-1 is a potent and specific Hec1 inhibitor, which disrupts Hec1-Nek2 protein interaction.
Docetaxel Trihydrate ^New

Docetaxel, an analog of paclitaxel, is an inhibitor of depolymerisation of microtubules by binding to stabilized microtubules.
Combretastatin A4 ^New

Combretastatin A4 is a microtubule-targeting agent that binds β-tubulin with K_d of 0.4 μM.Phase 3.
Docetaxel

Docetaxel, an analog of paclitaxel, is an inhibitor of depolymerisation of microtubules by binding to stabilized microtubules.
Vincristine sulfate

Vincristine sulfate is an inhibitor of polymerization of microtubules by binding to tubulin with IC50 of 32 μM in a cell-free assay.
Nocodazole

Nocodazole is a rapidly-reversible inhibitor of microtubule polymerization, also inhibits Abl, Abl(E255K) and Abl(T315I) with IC50 of 0.21 μM, 0.53 μM and 0.64 μM in cell-free assays, respectively. Nocodazole improves the CRISPR-mediated HDR efficiency and has an additive effect on enhancing precise genome editing.
Vinorelbine Tartrate

Vinorelbine Tartrate is a semi-synthetic vinca alkaloid, and inhibits mitosis through interaction with tubulin.
Cabazitaxel

Cabazitaxel is a semi-synthetic derivative of a natural taxoid that kills cancer cells by inhibiting cell division and growth. Cabazitaxel exerts its effects by inhibiting microtubule growth and assembly, processes that are essential for cells to divide.

Features:A semi-synthetic derivative of a natural taxoid.
Patupilone (EPO906, Epothilone B)

Patupilone (EPO906, Epothilone B) is a paclitaxel-like microtubule-stabilizing agent with EC_0.01 of 1.8 μM. Phase 2.

Choose Your Country or Region

By Signaling Pathways

By product type

Paclitaxel

Cited by 22 Publications

6 Customer Reviews

Purity & Quality Control

Choose Selective Microtubule Associated Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Paclitaxel SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-03-27)

Tech Support

Frequently Asked Questions

Microtubule Associated Signaling Pathway Map

Related Microtubule Associated Products0

Choose Your Country or Region

By Signaling Pathways

By product type

Paclitaxel

Cited by 22 Publications

6 Customer Reviews

Purity & Quality Control

Choose Selective Microtubule Associated Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Paclitaxel SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-03-27)

Tech Support

Frequently Asked Questions

Microtubule Associated Signaling Pathway Map

Related Microtubule Associated Products0

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)